Zelira Therapeutics Ltd
G1G
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
8
Stocks News & Analysis
stocks
Samsung and SK Hynix lead chip selloff as China competition fears grow
CXMT’s claimed tech breakthrough and an AI industry leader’s comments are weighing on stocks across the sector.
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
Stronger copper, aluminum and zinc prices offset by iron ore.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,869.00 | 52.50 | -0.59% |
| CAC 40 | 7,873.11 | 45.48 | 0.58% |
| DAX 40 | 25,298.61 | 38.71 | 0.15% |
| Dow JONES (US) | 51,446.98 | 223.12 | -0.43% |
| FTSE 100 | 10,724.86 | 74.53 | 0.70% |
| HKSE | 24,314.17 | 31.05 | -0.13% |
| NASDAQ | 26,634.78 | 569.61 | -2.09% |
| Nikkei 225 | 67,744.29 | 33.23 | -0.05% |
| NZX 50 Index | 13,760.39 | 10.79 | 0.08% |
| S&P 500 | 7,701.83 | 103.62 | -1.33% |
| S&P/ASX 200 | 8,727.90 | 56.00 | -0.64% |
| SSE Composite Index | 3,767.23 | 33.64 | -0.88% |